List of works - Hamid Hasson

A case of HIV-associated fever of unknown origin: deficit of IL-1β antagonistic activity and resolution with monocyte–granulocyte apheresis

Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.

scientific article published in December 2006

Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients

scientific article published on February 2016

Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.

scientific article published on 16 December 2015

Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors

scientific article published on 5 January 2017

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin

scientific article published on October 2015

Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure

article

Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.

scientific article

Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment

scientific article

Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART.

scientific article published on January 2002

HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy

scientific article published on 19 May 2020

Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.

scientific article

Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients

scientific article published in March 2006

Immunovirological improvement in partially HAART responder HIV-infected patients by monocyte adsorption apheresis

article

Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.

scientific article published on 19 January 2016

In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders

scientific article

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

scientific article

Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

scientific article published on September 2004

Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin

scientific article

Monotherapy With Atazanavir as a Simplificati Strategy

Mother-to-child transmission of TT virus: sequence analysis of non-coding region of TT virus in infected mother-infant pairs.

scientific article published on April 2002

NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.

scientific article published on 18 April 2017

Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs

scientific article published on 28 March 2013

Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals

article

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

scientific article published on 22 December 2016

Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.

scientific article published in May 2005

Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients

scientific article

Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis

scientific article published on 20 December 2016

Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy

scientific article published in February 2004

Prevalence of type 2 diabetes mellitus and its predictive factors in Italy: a comparison between HIV-infected and uninfected subjects.

scientific article published on 8 November 2010

Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.

scientific article published in April 2004

Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients

scientific article published in January 2004

Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus

scientific article published on 6 February 2013

Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy

scientific article

Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters.

scientific article published in May 2002

Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.

scientific article

Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure

scientific article

Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman

scientific article published on 24 October 2014

TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.

scientific article

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

scientific article published in August 2004

The introduction of the fusion inhibitors in the HAART-regimens.

scientific article published in April 2004

List of works by Hamid Hasson

A case of HIV-associated fever of unknown origin: deficit of IL-1β antagonistic activity and resolution with monocyte–granulocyte apheresis

Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.

Diagnostic accuracy of APRI, FIB-4 and Forns for the detection of liver cirrhosis in HIV/HCV-coinfected patients

Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.

Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin

Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure

Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.

Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment

Granulocyte/monocyte apheresis induces sustained increases in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART.

HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy

Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.

Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients

Immunovirological improvement in partially HAART responder HIV-infected patients by monocyte adsorption apheresis

Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C.

In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation.

Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin

Monotherapy With Atazanavir as a Simplificati Strategy

Mother-to-child transmission of TT virus: sequence analysis of non-coding region of TT virus in infected mother-infant pairs.

NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B.

Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs

Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program

Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.

Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients

Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis

Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy

Prevalence of type 2 diabetes mellitus and its predictive factors in Italy: a comparison between HIV-infected and uninfected subjects.

Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.

Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients

Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naive individuals infected with hepatitis C virus

Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy

Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters.

Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.

Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure

Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman

TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype.

The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.

The introduction of the fusion inhibitors in the HAART-regimens.